TXMD

+ Watchlist + Portfolio

TherapeuticsMD, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.03
52-Week Range: $0.99 – $2.95
Market Cap: $23.84M
P/E (TTM): —
EPS (TTM): -0.03
Dividend Yield: —

Advanced Metrics

Price/Book: 0.88
PEG Ratio: —
Return on Equity: -1.08%
Return on Assets: -2.88%
Gross Margin: 100.00%
Operating Margin: -32.22%
Profit Margin: -6.64%
Current Ratio: 3.22
Debt/Equity: 0.20
Total Debt: $5.56M
Free Cash Flow: $896.63K
Revenue Growth: -8.70%
Earnings Growth: -80.60%
Enterprise Value: $19.87M

TXMD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$69.96M	$1.30M	$1.76M	$3.02M
Cost of Revenue	$1.40M	$0.00	—	—
Gross Profit	$68.57M	$1.30M	—	—
Research & Development	$0.00	—	—	—
Selling, General & Admin	$56.71M	$8.90M	$6.10M	$6.85M
Operating Expenses	$57.90M	$9.82M	$6.61M	$7.24M
Operating Income	$10.66M	-$8.52M	-$4.84M	-$4.21M
EBITDA	$11.86M	-$7.60M	-$3.56M	-$3.02M
Pretax Income	$1.07M	-$7.74M	-$2.34M	-$653.00K
Income Tax	$0.00	-$43.00K	-$31.00K	$0.00
Net Income	$112.00M	-$10.28M	-$2.18M	-$569.00K
Diluted EPS	11.96	-0.98	-0.19	-0.05
Diluted Shares	9.37M	10.44M	11.53M	11.57M

TXMD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$38.07M	$4.33M	$5.06M	$7.48M
Receivables	$0.00	$3.09M	$3.56M	$3.52M
Current Assets	$55.35M	$11.80M	$12.26M	$14.45M
Total Assets	$90.46M	$43.31M	$38.82M	$37.66M
Current Liabilities	$46.84M	$6.85M	$5.17M	$4.79M
Total Debt	$8.76M	$8.01M	$7.17M	$6.10M
Total Liabilities	$55.31M	$14.02M	$11.45M	$10.78M
Retained Earnings	-$939.36M	-$949.64M	-$951.82M	-$952.39M
Shareholders' Equity	$35.14M	$29.29M	$27.37M	$26.88M
Working Capital	$8.51M	$4.94M	$7.09M	$9.66M

TXMD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$9.36M	-$23.08M	$1.17M	$2.45M
Capital Expenditure	-$355.00K	—	—	—
Free Cash Flow	$9.00M	-$23.08M	$1.17M	$2.45M
Depreciation & Amortisation	$1.20M	$922.00K	$1.28M	$1.19M
Stock-Based Compensation	$11.57M	$1.27M	$264.00K	$75.00K
Investing Cash Flow	-$355.00K	$0.00	—	—
Financing Cash Flow	-$235.21M	$3.15M	$0.00	—
Share Repurchases	-$38.66M	$0.00	—	—
Net Change in Cash	-$15.80M	-$44.99M	$732.00K	$2.42M

TXMD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$393.00K	$952.00K	$784.00K	$893.00K	$724.00K
Selling, General & Admin	$1.49M	$1.55M	$1.52M	$2.29M	$1.35M
Operating Expenses	$1.59M	$1.65M	$1.61M	$2.39M	$1.45M
Operating Income	-$1.19M	-$695.00K	-$830.00K	-$1.50M	-$723.00K
EBITDA	-$1.10M	$643.00K	$149.00K	-$3.24M	-$629.00K
Pretax Income	-$668.00K	$545.00K	$50.00K	-$580.00K	$103.00K
Income Tax	-$32.00K	$0.00	$0.00	$32.00K	$0.00
Net Income	-$653.00K	$551.00K	$152.00K	-$619.00K	$95.00K
Diluted EPS	-0.06	0.05	0.01	—	0.01
Diluted Shares	11.55M	11.57M	11.57M	—	11.64M

TXMD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.75M	$6.07M	$7.12M	$7.48M	$8.42M
Receivables	$3.00M	$3.74M	$3.67M	$3.52M	$3.87M
Current Assets	$12.51M	$13.46M	$14.50M	$14.45M	$15.26M
Total Assets	$38.24M	$38.50M	$38.67M	$37.66M	$37.58M
Current Liabilities	$4.74M	$4.66M	$4.95M	$4.79M	$4.91M
Total Debt	$6.97M	$6.60M	$6.48M	$6.10M	$5.83M
Total Liabilities	$11.50M	$11.21M	$11.23M	$10.78M	$10.61M
Retained Earnings	-$952.48M	-$951.92M	-$951.77M	-$952.39M	-$952.30M
Shareholders' Equity	$26.74M	$27.29M	$27.44M	$26.88M	$26.97M
Working Capital	$7.77M	$8.80M	$9.56M	$9.66M	$10.35M

TXMD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$699.00K	$381.00K	$999.00K	$375.00K	$944.00K
Free Cash Flow	$699.00K	$381.00K	$999.00K	$375.00K	$944.00K
Depreciation & Amortisation	$95.00K	$96.00K	$96.00K	$906.00K	$94.00K
Stock-Based Compensation	$23.00K	$1.00K	$0.00	$51.00K	$2.00K
Net Change in Cash	$686.00K	$324.00K	$1.05M	$368.00K	$936.00K

Market Snapshot

About

TherapeuticsMD is a pharmaceutical company focused on developing and commercializing products for women, including hormone therapy, contraception, and other treatments. The company specializes in products addressing pregnancy prevention, menopause management, and reproductive health.